Tags

Type your tag names separated by a space and hit enter

Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine.
Cell Rep. 2023 Jan 31; 42(1):111998.CR

Abstract

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants.

Links

PMC Free PDF

Authors+Show Affiliations

Tauzin A
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Nicolas A
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Ding S
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Benlarbi M
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Medjahed H
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Chatterjee D
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Dionne K
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Gong SY
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
Gendron-Lepage G
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Bo Y
Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Perreault J
Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
Goyette G
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Gokool L
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Arlotto P
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Morrisseau C
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
Tremblay C
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
Martel-Laferrière V
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
De Serres G
Institut National de Santé Publique du Québec, Quebec, QC H2P 1E2, Canada.
Levade I
Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
Kaufmann DE
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada; Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University of Lausanne, 1011 Lausanne, Switzerland.
Côté M
Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Bazin R
Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
Finzi A
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@umontreal.ca.

MeSH

HumansSARS-CoV-2COVID-19Vaccines, SyntheticMutationAntibodies, ViralAntibodies, Neutralizing

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

36656710

Citation

Tauzin, Alexandra, et al. "Spike Recognition and Neutralization of SARS-CoV-2 Omicron Subvariants Elicited After the Third Dose of mRNA Vaccine." Cell Reports, vol. 42, no. 1, 2023, p. 111998.
Tauzin A, Nicolas A, Ding S, et al. Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Rep. 2023;42(1):111998.
Tauzin, A., Nicolas, A., Ding, S., Benlarbi, M., Medjahed, H., Chatterjee, D., Dionne, K., Gong, S. Y., Gendron-Lepage, G., Bo, Y., Perreault, J., Goyette, G., Gokool, L., Arlotto, P., Morrisseau, C., Tremblay, C., Martel-Laferrière, V., De Serres, G., Levade, I., ... Finzi, A. (2023). Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. Cell Reports, 42(1), 111998. https://doi.org/10.1016/j.celrep.2023.111998
Tauzin A, et al. Spike Recognition and Neutralization of SARS-CoV-2 Omicron Subvariants Elicited After the Third Dose of mRNA Vaccine. Cell Rep. 2023 Jan 31;42(1):111998. PubMed PMID: 36656710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Spike recognition and neutralization of SARS-CoV-2 Omicron subvariants elicited after the third dose of mRNA vaccine. AU - Tauzin,Alexandra, AU - Nicolas,Alexandre, AU - Ding,Shilei, AU - Benlarbi,Mehdi, AU - Medjahed,Halima, AU - Chatterjee,Debashree, AU - Dionne,Katrina, AU - Gong,Shang Yu, AU - Gendron-Lepage,Gabrielle, AU - Bo,Yuxia, AU - Perreault,Josée, AU - Goyette,Guillaume, AU - Gokool,Laurie, AU - Arlotto,Pascale, AU - Morrisseau,Chantal, AU - Tremblay,Cécile, AU - Martel-Laferrière,Valérie, AU - De Serres,Gaston, AU - Levade,Inès, AU - Kaufmann,Daniel E, AU - Côté,Marceline, AU - Bazin,Renée, AU - Finzi,Andrés, Y1 - 2023/01/09/ PY - 2022/8/3/received PY - 2022/11/28/revised PY - 2023/1/4/accepted PY - 2023/1/20/pubmed PY - 2023/2/7/medline PY - 2023/1/19/entrez KW - B cell responses KW - COVID-19 KW - CP: Immunology KW - Omicron subvariants KW - SARS-CoV-2 KW - coronavirus KW - humoral responses KW - hybrid immunity KW - neutralization KW - spike glycoproteins KW - third mRNA vaccine dose SP - 111998 EP - 111998 JF - Cell reports JO - Cell Rep VL - 42 IS - 1 N2 - Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariants have recently emerged, becoming the dominant circulating strains in many countries. These variants contain a large number of mutations in their spike glycoprotein, raising concerns about vaccine efficacy. In this study, we evaluate the ability of plasma from a cohort of individuals that received three doses of mRNA vaccine to recognize and neutralize these Omicron subvariant spikes. We observed that BA.4/5 and BQ.1.1 spikes are markedly less recognized and neutralized compared with the D614G and other Omicron subvariant spikes tested. Also, individuals who have been infected before or after vaccination present better humoral responses than SARS-CoV-2-naive vaccinated individuals, thus indicating that hybrid immunity generates better humoral responses against these subvariants. SN - 2211-1247 UR - https://www.unboundmedicine.com/medline/citation/36656710/Spike_recognition_and_neutralization_of_SARS_CoV_2_Omicron_subvariants_elicited_after_the_third_dose_of_mRNA_vaccine_ DB - PRIME DP - Unbound Medicine ER -